Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Key Inclusion Criteria:

• Histologically-confirmed follicular lymphoma (FL) (Grade 1, 2, or 3a)

• Relapsed/refractory (R/r) disease after first-line chemoimmunotherapy and high-riskdisease with relapse or progression within 24 months of the initial course ofchemoimmunotherapy (ie, POD24), Or r/r disease after ≥ 2 prior systemic lines oftherapy

• Clinical indication for treatment.

• At least 1 measurable lesion per the Lugano Classification {Cheson 2014}

• Adequate renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

• Presence of large B cell lymphoma or transformed FL

• Small lymphocytic lymphoma

• Lymphoplasmacytic lymphoma

• Full-thickness involvement of the gastric wall by lymphoma

• FL Grade 3b

• Prior CD19-targeted therapy

• Prior CAR therapy or other genetically modified T-cell therapy

• Uncontrolled fungal, bacterial, viral, or other infection

• Active Infection with human immunodeficiency virus, hepatitis B virus or hepatitis Cvirus

• History or presence of a clincially significant central nervous system (CNS)disorder.

• History of autoimmune disease

• Known history or CNS lymphoma involvement

• Cardiac lymphoma involvement

• History of clinically significant cardiac disease 6 months before randomization

• Neuropathy greater than grade 2

• Females who are pregnant or breastfeeding

• Individuals of both genders who are not willing to practice birth control

• Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube,indwelling Foley catheter, biliary drain, G/J-tube, pleural/peritoneal/pericardialcatheter, or Ommaya reservoirs). Dedicated central venous access catheters such asPort-a-Cath or Hickman catheter are permitted.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.